European Respiratory Journal

Article	Citations
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension	690
ERS/ATS technical standard on interpretive strategies for routine lung function tests	505
Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary	370
ERS statement on chronic thromboembolic pulmonary hypertension	327
Cardiopulmonary recovery after COVID-19: an observational prospective multicentre trial	294
Pulmonary function and radiological features 4 months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study	292
ERS clinical practice guidelines on treatment of sarcoidosis	289
Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes	275
Dyspnoea, lung function and CT findings 3 months after hospital admission for COVID-19	237
Risk factors for post-COVID-19 condition in previously hospitalised children using the ISARIC Global follow-up protocol: a prospective cohort study	209
Official ERS technical standard: Global Lung Function Initiative reference values for static lung volumes in individuals of European ancestry	188
COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension	153
Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline	150
Deconditioning as main mechanism of impaired exercise response in COVID-19 survivors	150
The impact of COVID-19 on patients with asthma	150
World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update	142
Endothelial cells in the pathogenesis of pulmonary arterial hypertension	139
ERS clinical practice guidelines: high-flow nasal cannula in acute respiratory failure	139
Cardiopulmonary exercise capacity and limitations 3 months after COVID-19 hospitalisation	137
European Respiratory Society clinical practice guidelines for the diagnosis of asthma in children aged 5–16 years	131
Medium-term impact of COVID-19 on pulmonary function, functional capacity and quality of life	130
Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis	126
E-cigarette use and respiratory disorders: an integrative review of converging evidence from epidemiological and laboratory studies	123
European Respiratory Society guidelines for the management of children and adolescents with bronchiectasis	120
Mesenchymal stromal cell extracellular vesicles rescue mitochondrial dysfunction and improve barrier integrity in clinically relevant models of ARDS	120

Vaccination against COVID-19: insight from arterial and venous thrombosis occurrence using data from VigiBase	109
Inspiratory muscle training enhances recovery post-COVID-19: a randomised controlled trial	107
Genetic analysis of obstructive sleep apnoea discovers a strong association with cardiometabolic health	106
European Respiratory Society guidelines for the diagnosis of asthma in adults	105
Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with self-collected nasal swabversusprofessional-collected nasopharyngeal swab	103
Plasma ACE2 activity is persistently elevated following SARS-CoV-2 infection: implications for COVID-19 pathogenesis and consequences	102
External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry	102
European Respiratory Society statement on long COVID follow-up	99
Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator	99
Diffusion capacity abnormalities for carbon monoxide in patients with COVID-19 at 3-month follow-up	98
Between inflammation and thrombosis: endothelial cells in COVID-19	96
Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial	95
Chronic respiratory diseases are predictors of severe outcome in COVID-19 hospitalised patients: a nationwide study	94
Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation	93
Rothia mucilaginosais an anti-inflammatory bacterium in the respiratory tract of patients with chronic lung disease	92
Asthma remission: what is it and how can it be achieved?	91
Gauging the impact of the COVID-19 pandemic on tuberculosis services: a global study	91
Transbronchial mediastinal cryobiopsy in the diagnosis of mediastinal lesions: a randomised trial	90
Idiopathic pulmonary fibrosis: state of the art for 2023	90
The physiological basis of pulmonary arterial hypertension	89
The burden of asthma, hay fever and eczema in children in 25 countries: GAN Phase I study	84
Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry	83
The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM)	77
Hyperventilation as one of the mechanisms of persistent dyspnoea in SARS-CoV-2 survivors	76
Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis	74
Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension	71
Tuberculosis and COVID-19 co-infection: description of the global cohort	71
Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long-COVID symptoms	71
Asthma and COVID-19 risk: a systematic review and meta-analysis	70
Progressive pulmonary fibrosis: an expert group consensus statement	68
Interstitial lung disease increases susceptibility to and severity of COVID-19	67
Phenotyping long COVID	67
The high mental health burden of “Long COVID” and its association with on-going physical and respiratory symptoms in all adults discharged from hospital	67
Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry	66
Topological data analysis reveals genotype–phenotype relationships in primary ciliary dyskinesia	66
“You can leave your mask on”: effects on cardiopulmonary parameters of different airway protective masks at rest and during maximal exercise	66
Metabolomic analyses reveal new stage-specific features of COVID-19	65
Asthma management in low and middle income countries: case for change	65
Comorbid insomnia and sleep apnoea is associated with all-cause mortality	63
Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study	63
Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: results from the COMPERA registry	62
Development and validation of a deep learning algorithm detecting 10 common abnormalities on chest radiographs	62
Lung function trajectory in progressive fibrosing interstitial lung disease	62
Emergence of bedaquiline resistance in a high tuberculosis burden country	62
Dexamethasone in hospitalised COVID-19 patients not on intensive respiratory support	62
The burden of asthma, hay fever and eczema in adults in 17 countries: GAN Phase I study	61
Pulmonary infection by SARS-CoV-2 induces senescence accompanied by an inflammatory phenotype in severe COVID-19: possible implications for viral mutagenesis	61
Long COVID: to investigate immunological mechanisms and sex/gender related aspects as fundamental steps for tailored therapy	60
Short-acting β2-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study	60
Characterisation of paediatric pulmonary hypertensive vascular disease from the PPHNet Registry	60

Clinical, radiological and pathological findings in patients with persistent lung disease following SARS-CoV-2 infection	59
Elevated pulmonary vascular resistance predicts mortality in COPD patients	58
Screening for pulmonary arterial hypertension in adults carrying aBMPR2mutation	57
Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial	57
Epigenetics and pulmonary diseases in the horizon of precision medicine: a review	57
European Respiratory Society guidelines on transbronchial lung cryobiopsy in the diagnosis of interstitial lung diseases	55
Stoppingversuscontinuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study)	55
Macrophage-derived IL-6 trans-signalling as a novel target in the pathogenesis of bronchopulmonary dysplasia	54
Endothelial eNAMPT amplifies pre-clinical acute lung injury: efficacy of an eNAMPT-neutralising monoclonal antibody	52
When things go wrong: exploring possible mechanisms driving the progressive fibrosis phenotype in interstitial lung diseases	52
TNF-mediated alveolar macrophage necroptosis drives disease pathogenesis during respiratory syncytial virus infection	50
Imaging of pulmonary hypertension in adults: a position paper from the Fleischner Society	50
Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma	50
World Health Organization treatment outcome definitions for tuberculosis: 2021 update	50
Identifying early pulmonary arterial hypertension biomarkers in systemic sclerosis: machine learning on proteomics from the DETECT cohort	49
In critically ill patients, anti-anaerobic antibiotics increase risk of adverse clinical outcomes	49
Steroid use in elderly critically ill COVID-19 patients	48
Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial	48
ERS statement on paediatric long-term noninvasive respiratory support	48
Functional lower airways genomic profiling of the microbiome to capture active microbial metabolism	48
Efficacy of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease	47
Chest radiography or computed tomography for COVID-19 pneumonia? Comparative study in a simulated triage setting	47
The burden of progressive fibrotic interstitial lung disease across the UK	47
Computed tomography-based radiomics decodes prognostic and molecular differences in interstitial lung disease related to systemic sclerosis	47
Heterogeneity within and between physician-diagnosed asthma and/or COPD: NOVELTY cohort	47
Long-term exposure to low-level air pollution and incidence of asthma: the ELAPSE project	47
Effect of highversuslow dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label, randomised clinical trial	46
Drug-induced interstitial lung disease	46
Intracellular hydroxyproline imprinting following resolution of bleomycin-induced pulmonary fibrosis	46
Bone morphogenetic protein 4 inhibits pulmonary fibrosis by modulating cellular senescence and mitophagy in lung fibroblasts	45
Cardiopulmonary exercise testing might be helpful for interpretation of impaired pulmonary function in recovered COVID-19 patients	45
Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial	44
Autoimmunity to annexin A2 predicts mortality among hospitalised COVID-19 patients	44
Mesenchymal stromal (stem) cell therapy modulates miR-193b-5p expression to attenuate sepsis-induced acute lung injury	44
Pulse oximeter measurements vary across ethnic groups: an observational study in patients with COVID-19	44
ERS/ESTS statement on the management of pleural infection in adults	43
A prospective multicentre diagnostic accuracy study for the Truenat tuberculosis assays	42
Outcome of acute hypoxaemic respiratory failure: insights from the LUNG SAFE Study	42
Treatment of cystic fibrosis airway cells with CFTR modulators reverses aberrant mucus propertiesviahydration	42
Blood eosinophil counts in the general population and airways disease: a comprehensive review and meta-analysis	42
New definitions of pre-extensively and extensively drug-resistant tuberculosis: update from the World Health Organization	42
Air pollutants, genetic susceptibility and risk of incident idiopathic pulmonary fibrosis	42
Nintedanib in children and adolescents with fibrosing interstitial lung diseases	42
Tests for tuberculosis infection: landscape analysis	41
A randomised controlled trial of the effect of a connected inhaler system on medication adherence in uncontrolled asthmatic patients	41
Safety and efficacy of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis and carrying a telomere-related gene mutation	41
Effects of COVID-19 protective face masks and wearing durations on respiratory haemodynamic physiology and exhaled breath constituents	41
Influenza virus infection increases ACE2 expression and shedding in human small airway epithelial cells	40
Inhaled corticosteroids downregulate SARS-CoV-2-related genes in COPD: results from a randomised controlled trial	40
High-doseversuslow-dose prednisolone in symptomatic patients with post-COVID-19 diffuse parenchymal lung abnormalities: an open-label, randomised trial (the COLDSTER trial)	40
Diagnostic, prognostic and differential-diagnostic relevance of pulmonary haemodynamic parameters during exercise: a systematic review	40
Prognostic factors for adverse outcomes in patients with COVID-19: a field-wide systematic review and meta-analysis	40
Complications of nasal and pharyngeal swabs: a relevant challenge of the COVID-19 pandemic?	40
Theratyping cystic fibrosisin vitroin ALI culture and organoid models generated from patient-derived nasal epithelial conditionally reprogrammed stem cells	39
Intravenous methylprednisolone pulses in hospitalised patients with severe COVID-19 pneumonia: a double-blind, randomised, placebo-controlled trial	39
Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma	39
Plasma mediators in patients with severe COVID-19 cause lung endothelial barrier failure	39
Two sides of the same coin? A review of the similarities and differences between idiopathic pulmonary fibrosis and rheumatoid arthritis-associated interstitial lung disease	39
Home monitoring reduced short stay admissions in suspected COVID-19 patients: COVID-box project	38
Early-life respiratory tract infections and the risk of school-age lower lung function and asthma: a meta-analysis of 150 000 European children	38
T2-high asthma phenotypes across lifespan	38
The effectiveness of contact investigation among contacts of tuberculosis patients: a systematic review and meta-analysis	38
Biomarker signatures for progressive idiopathic pulmonary fibrosis	38
Dynamics of SARS-CoV-2 shedding in the respiratory tract depends on the severity of disease in COVID-19 patients	37
Multi-omics links IL-6 trans-signalling with neutrophil extracellular trap formation andHaemophilusinfection in COPD	37
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations	37
Impact of the COVID-19 pandemic on tuberculosis laboratory services in Europe	37
Lung function and cardiovascular disease: a two-sample Mendelian randomisation study	37
Selexipag for the treatment of chronic thromboembolic pulmonary hypertension	37
Point-of-care lung ultrasound assessment for risk stratification and therapy guiding in COVID-19 patients: a prospective noninterventional study	37
The methyl-CpG-binding domain 2 facilitates pulmonary fibrosis by orchestrating fibroblast to myofibroblast differentiation	37
Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg−1rifampicin	37
Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial	36
Theratyping cystic fibrosis patients to guide elexacaftor/tezacaftor/ivacaftor out-of-label prescription	36
The French Compassionate Program of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with advanced lung disease and no F508delCFTRvariant	36
Prevalence of pulmonary embolism in patients with COVID-19 at the time of hospital admission	36
Awake prone positioning and oxygen therapy in patients with COVID-19: the APRONOX study	36
Residual symptoms and lower lung function in patients recovering from SARS-CoV-2 infection	36
Triple therapy in uncontrolled asthma: a network meta-analysis of phase III studies	36
Identification of a novel subset of alveolar type 2 cells enriched in PD-L1 and expanded following pneumonectomy	35

Air pollution and COVID-19: clearing the air and charting a post-pandemic course: a joint workshop report of ERS, ISEE, HEI and WHO	35
Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension	35
The causal relationship between gastro-oesophageal reflux disease and idiopathic pulmonary fibrosis: a bidirectional two-sample Mendelian randomisation study	35
Childhood asthma: pathogenesis and phenotypes	35
Recommendations for respiratory syncytial virus surveillance at the national level	35
Lung transplantation for sarcoidosis: outcome and prognostic factors	35
Epidemiology of pleural empyema in English hospitals and the impact of influenza	35
Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension	35
Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model	35
Serum and pulmonary uric acid in pulmonary arterial hypertension	34
ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia	34
Profiling of lung SARS-CoV-2 and influenza virus infection dissects virus-specific host responses and gene signatures	34
Transcriptomics of bronchoalveolar lavage cells identifies new molecular endotypes of sarcoidosis	34
Assessment of chronic bronchitis and risk factors in young adults: results from BAMSE	34
Hypoxic burden and heart rate variability predict stroke incidence in sleep apnoea	34
Dyspnoea and respiratory muscle ultrasound to predict extubation failure	34
Echocardiographic probability of pulmonary hypertension: a validation study	34
High eosinophil counts predict decline in FEV1: results from the CanCOLD study	34
Survival estimates in European cystic fibrosis patients and the impact of socioeconomic factors: a retrospective registry cohort study	34
Chronic pulmonary aspergillosis: prevalence, favouring pulmonary diseases and prognosis	33
A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19	33
Incidence and disease burden of coal workers’ pneumoconiosis worldwide, 1990–2019: evidence from the Global Burden of Disease Study 2019	33
Asthma and COVID-19: do we finally have answers?	33
Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19: a randomised double-blinded placebo-controlled trial	33
Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry	33
A randomised trial of prednisoloneversusprednisolone and itraconazole in acute-stage allergic bronchopulmonary aspergillosis complicating asthma	33
The association between SARS-CoV-2 RT-PCR cycle threshold and mortality in a community cohort	32
A large-scale genome-wide association analysis of lung function in the Chinese population identifies novel loci and highlights shared genetic aetiology with obesity	32
Proteinase release from activated neutrophils in mechanically ventilated patients with non-COVID-19 and COVID-19 pneumonia	32
Crucial role of fatty acid oxidation in asthmatic bronchial smooth muscle remodelling	32
European Respiratory Society statement on familial pulmonary fibrosis	32
Neonatal metabolome of caesarean section and risk of childhood asthma	31
Location of eosinophils in the airway wall is critical for specific features of airway hyperresponsiveness and T2 inflammation in asthma	31
Novel avenues to approach non-CPAP therapy and implement comprehensive obstructive sleep apnoea care	31
Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group	31
Noninvasive strategies in COVID-19: epistemology, randomised trials, guidelines, physiology	31
Risk factors for mortality in patients with COVID-19 needing extracorporeal respiratory support	31
Sleep laboratories reopening and COVID-19: a European perspective	31
Why asthma might surprisingly protect against poor outcomes in COVID-19	31
Mortality trends in pulmonary arterial hypertension in Canada: a temporal analysis of survival per ESC/ERS guideline era	31
Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial	30
Blood eosinophil counts and the development of obstructive lung disease: the Kangbuk Samsung Health Study	30
Longitudinal course of clinical lung clearance index in children with cystic fibrosis	30
Epidemiological cut-off values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing ofM. tuberculosis	30
Randomised trial of the P2X3receptor antagonist sivopixant for refractory chronic cough	30
Association of early-life factors with prematurity-associated lung disease: prospective cohort study	30
Heterogeneity of treatment response in bronchiectasis clinical trials	30
Trends in risk stratification, in-hospital management and mortality of patients with acute pulmonary embolism: an analysis from the China pUlmonary thromboembolism REgistry Study (CURES)	29
Neutrophil dysfunction in bronchiectasis: an emerging role for immunometabolism	29
Genome sequencing reveals underdiagnosis of primary ciliary dyskinesia in bronchiectasis	29
Fine particulate matter components and interstitial lung disease in rheumatoid arthritis	29
Adjunctive treatment with oral dexamethasone in non-ICU patients hospitalised with community-acquired pneumonia: a randomised clinical trial	29
Nitrogen dioxide increases the risk of mortality in idiopathic pulmonary fibrosis	29
Association of obstructive sleep apnoea with cardiovascular events in women and men with acute coronary syndrome	29
Exercise capacity impairment after COVID-19 pneumonia is mainly caused by deconditioning	28
Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline	28
Genetic overlap between idiopathic pulmonary fibrosis and COVID-19	28
Altered pulmonary blood volume distribution as a biomarker for predicting outcomes in COVID-19 disease	28
Novel mechanisms of action contributing to benralizumab's potent anti-eosinophilic activity	28
Prognostic factors of severe community-acquired staphylococcal pneumonia in France	28
Markers of disease activity in COPD: an 8-year mortality study in the ECLIPSE cohort	28
European Respiratory Society clinical practice guideline: palliative care for people with COPD or interstitial lung disease	28
Sleep apnoea and heart failure	28
The rescue of F508del-CFTR by elexacaftor/tezacaftor/ivacaftor (Trikafta) in human airway epithelial cells is underestimated due to the presence of ivacaftor	28
Low-dose oral corticosteroids in asthma associates with increased morbidity and mortality	28
Single-cell RNA sequencing identifies G-protein coupled receptor 87 as a basal cell marker expressed in distal honeycomb cysts in idiopathic pulmonary fibrosis	27
EmPHasis-10 as a measure of health-related quality of life in pulmonary arterial hypertension: data from PHAR	27
Performance of a digital signal processing algorithm for the accurate quantification of cough frequency	27
Plasma cell but not CD20-mediated B-cell depletion protects from bleomycin-induced lung fibrosis	27
Obstructive sleep apnoea and 5-year cognitive decline in the elderly	27
Development of Core Outcome Measures sets for paediatric and adult Severe Asthma (COMSA)	27
Interstitial lung disease before and after COVID-19: a double threat?	27
Monocytes in sarcoidosis are potent tumour necrosis factor producers and predict disease outcome	27
Pneumomediastinum in COVID-19: a phenotype of severe COVID-19 pneumonitis? The results of the UK POETIC survey	27
Effects of intubation timing in patients with COVID-19 throughout the four waves of the pandemic: a matched analysis	27
Acute respiratory distress syndrome is associated with impaired alveolar macrophage efferocytosis	26
Human lungs show limited permissiveness for SARS-CoV-2 due to scarce ACE2 levels but virus-induced expansion of inflammatory macrophages	26
Nasopharyngeal metatranscriptome profiles of infants with bronchiolitis and risk of childhood asthma: a multicentre prospective study	26
Reduction in asthma admissions during the COVID-19 pandemic: consequence of public health measures in Singapore	26
Prenatal and prepubertal exposures to tobacco smoke in men may cause lower lung function in future offspring: a three-generation study using a causal modelling approach	26
Genetically proxied interleukin-6 receptor inhibition: opposing associations with COVID-19 and pneumonia	26
Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trial	26
A systematic review of blood biomarkers with individual participant data meta-analysis of matrix metalloproteinase-7 in idiopathic pulmonary fibrosis	26
PaO2/FIO2ratio: the mismeasure of oxygenation in COVID-19	26
Expectation and dyspnoea: the neurobiological basis of respiratory nocebo effects	26
AICAR decreases acute lung injury by phosphorylating AMPK and upregulating heme oxygenase-1	26
Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma	26
SPLUNC1: a novel marker of cystic fibrosis exacerbations	25
Intermittent hypoxia-related alterations in vascular structure and function: a systematic review and meta-analysis of rodent data	25
Antigen identification and avoidance on outcomes in fibrotic hypersensitivity pneumonitis	25
Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with professional-collected nasalversusnasopharyngeal swab	25
Clinical outcomes of bronchiectasis in India: data from the EMBARC/Respiratory Research Network of India registry	25
Prolonged higher dose methylprednisoloneversusconventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS)	25
An integrated multiomic and quantitative label-free microscopy-based approach to study pro-fibrotic signalling inex vivohuman precision-cut lung slices	25
Personal exposure to air pollution and respiratory health of COPD patients in London	25